CytoDyn Files IND and Protocol for Phase 1b/2 Clinical Trial in Metastatic Triple-Negative Breast Cancer with PRO 140 (Leronlimab) Nov 05, 2018 6:00am EST
CytoDyn Interim Chief Medical Officer Dr. Richard Pestell to Keynote 11th Annual Conference on Stem Cell and Regenerative Medicine Oct 11, 2018 6:00am EDT
CytoDyn Announces Strategy to Complete Development of Novel ProstaGene Gene-based Prostate Cancer Prognostic Test Oct 09, 2018 6:00am EDT
CytoDyn Announces Plan to Develop PRO 140 for Metastatic Triple-Negative Breast Cancer as Initial Oncology Indication Sep 05, 2018 6:00am EDT
CytoDyn Signs Definitive Agreement to Acquire ProstaGene; Founder and CEO Dr. Richard Pestell to Join CytoDyn as Interim Chief Medical Officer Aug 28, 2018 6:00am EDT
CytoDyn, Inc.’s President and CEO, Nader Pourhassan, Ph.D., Discusses Company Research with Everett Jolly on Uptick Newswire’s “Stock Day” Podcast Aug 27, 2018 7:30am EDT
CytoDyn Announces Strong Preclinical Results Using PRO 140 in Human Colon Carcinoma Aug 15, 2018 6:00am EDT
